These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30615403)

  • 21. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
    Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
    Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of a Low-Cost, Sensitive PNA Clamping PCR Method for JAK2 V617F Variant Detection.
    Di Francia R; Crisci S; Muto T; Giancola C; Petriccone L; Catapano O; Cummarro A; Pinto A; Frigeri F
    J Appl Lab Med; 2020 Jul; 5(4):643-655. PubMed ID: 32407536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
    Fontanelli G; Baratè C; Ciabatti E; Guerrini F; Grassi S; Del Re M; Morganti R; Petrini I; Arici R; Barsotti S; Metelli MR; Danesi R; Galimberti S
    Int J Lab Hematol; 2015 Dec; 37(6):766-73. PubMed ID: 26189968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System.
    Kinz E; Muendlein A
    Methods Mol Biol; 2018; 1768():257-273. PubMed ID: 29717448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.
    Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F
    Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.
    Zapparoli GV; Jorissen RN; Hewitt CA; McBean M; Westerman DA; Dobrovic A
    BMC Cancer; 2013 Apr; 13():206. PubMed ID: 23617802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.
    Basquiera AL; Soria NW; Ryser R; Salguero M; Moiraghi B; Sackmann F; Sturich AG; Borello A; Berretta A; Bonafé M; Barral JM; Palazzo ED; García JJ
    Hematology; 2009 Dec; 14(6):323-30. PubMed ID: 19941738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation.
    Koksal V; Etlik O; Arican-Baris ST; Baris I
    Genet Test; 2007; 11(4):463-6. PubMed ID: 18294066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.
    Malysz J; Crisan D
    Ann Clin Lab Sci; 2009; 39(4):345-50. PubMed ID: 19880761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
    Larsen TS; Pallisgaard N; de Stricker K; Møller MB; Hasselbalch HC
    Hematology; 2009 Feb; 14(1):11-5. PubMed ID: 19154659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
    Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
    Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.